Genomic Surveillance Unit (Wellcome Sanger Institute)

The Genomic Surveillance Unit (Wellcome Sanger Institute) is dedicated to enhancing global human health through the accelerated application and impact of genomic surveillance. By providing essential products, tools, and services, the Genomic Surveillance Unit (Wellcome Sanger Institute) empowers its public health partners to incorporate genomic information into their crucial decision-making processes.

Located in Hinxton, CB10 1SA, GB, the Genomic Surveillance Unit (Wellcome Sanger Institute) combines expertise in genomics, data science, product development, and sequencing operations to create robust surveillance solutions for significant human diseases. Currently, the focus is on malaria, COVID-19, and various other respiratory viruses, ensuring comprehensive coverage and impactful results.

With a proven track record in implementing COVID-19 and malaria genomic surveillance streams, the Genomic Surveillance Unit (Wellcome Sanger Institute) supports partners worldwide at every stage, from sample collection and lab setup to training, data generation, and analysis. The Genomic Surveillance Unit (Wellcome Sanger Institute)’s mission is to continually increase the benefits to public health while improving the accessibility and quality of genomic surveillance data. Management is actively completing further detailed information about the Genomic Surveillance Unit (Wellcome Sanger Institute).

We invite the manager of the Genomic Surveillance Unit (Wellcome Sanger Institute) to create a customized and exclusive company showcase and product listing on our platform to further highlight your contributions to public health.